Spotlight commentary: Using real-world data for real-world evidence generation to advance drug repurposing

Drug repurposing has been presented as an attractive alternative approach to de novo drug development due to its lower costs, shorter development time, and higher success rate across the developmental and regulatory pipeline. Analysis of real-world data (RWD), collected from routine healthcare delivery, is one of the computational approaches to advance drug repurposing efforts.1 Several recent publications in the British Journal of Clinical Pharmacology (BJCP) have featured the use of RWD and/or drug repurposing.